-
Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval from the National Medical Products Administration (NMPA) for their SGLT2 inhibitor Jardiance (empagliflozin) aimed at treating adult chronic kidney disease (CKD). This pivotal approval marks a significant advancement in the management of CKD, further establishing…
-
True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development
•
True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over RMB 100 million (approximately USD 14 million) in a Series B+ financing round. This significant funding will be allocated to enhance research and development efforts, accelerate innovation in the surgical robot sector, and procure essential…
-
MicuRx Pharmaceuticals Secures NMPA Approval for MRX-4 and Contezolid Combination Therapy
•
Sino-US firm MicuRx Pharmaceuticals Inc. has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative anti-microbial agent MRX-4, in combination with contezolid (MRX-I). This novel treatment targets infections caused by drug-resistant Gram-positive bacteria, marking a significant advancement in antibiotic therapy. Overview…
-
Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China
•
Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999). This collaboration aims to enhance the reach of Stada’s cough and cold brands across hospital, pharmacy, and e-commerce channels in China. Key Brands Included in the Partnership The brands…
-
C2 Pharma Secures C-DMF Approval for Pilocarpine Nitrate API
•
Ireland-based C2 Pharma has announced the receipt of approval for a C-DMF (drug master file) concerning its pilocarbine nitrate API. This critical active pharmaceutical ingredient (API), produced in collaboration with C2’s Brazilian partner, Anidro do Brasil, plays a vital role in the formulation of ophthalmic medications. Key Features of Pilocarpine…
-
SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China
•
China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s SCG101 autologous T cell therapy has obtained tacit clinical trial approval in China. This marks a world-first clinical indication for the treatment of cholangiocarcinoma. SCG101’s Expanding Clinical IndicationsSCG101, a TCR-T cell therapy, targets specific hepatitis…
-
Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study
•
China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab (AK104), an innovative bispecific antibody targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has achieved its primary endpoint. The study combines the antibody with chemotherapy and optional bevacizumab for the first-line treatment of…
-
RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China
•
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete approval from the National Medical Products Administration (NMPA) for its fusion protein drug telitacicept, used in the treatment of systemic lupus erythematosus (SLE). This approval follows a multi-center, randomized, double-blind, placebo-controlled Phase III study involving…
